Nanexa’s Ph1 QM Liraglutide Study Delayed; SAB Completes Dosing in Ph1 T1DM Trial; Novartis’s Iptacopan IgAN sNDA Receives Priority Review; Ypsomed Partners with Ten23 for Patch Injector; JNJ Q1 ’24 Earnings
A series of cardiometabolic-related news items have been observed from Nanexa, SAB, Novartis, Ypsomed, and J&J. Below, FENIX provides highlights and insights for the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.